Related Experiment Video

Updated: Jul 8, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

[Protective effect of baicalin on mouse with Parkinson's disease induced by MPTP]

Xin Chen1, Nan Zhang, Hai-yan Zou

  • 1Department of Chinese Drug Pharmacology, College of Pharmacy, Capital Medical University, Beijing. chenxin4283@126.com

Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine
|January 5, 2008
PubMed
Abstract

Insights

Baicalin demonstrated a protective effect in a mouse model of Parkinson's disease, preventing dopaminergic neuron loss and dopamine depletion. However, short-term treatment did not significantly improve motor dysfunction in these Parkinson's disease mice.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Context:

  • Parkinson's disease (PD) is a progressive neurodegenerative disorder.
  • 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is commonly used to induce PD models in rodents.
  • Baicalin is a flavonoid with potential antioxidant and anti-inflammatory properties.

Purpose:

  • To investigate the neuroprotective effects of baicalin in an MPTP-induced mouse model of Parkinson's disease.

Summary:

  • MPTP successfully induced Parkinson's disease in C57BL mice, evidenced by motor deficits, reduced striatal dopamine, and loss of dopaminergic neurons.
  • Baicalin treatment (100 mg/kg) protected against dopaminergic neuron loss and maintained striatal dopamine levels.
  • Baicalin significantly increased glutathione (GSH) levels in the brain tissue.

Impact:

  • Baicalin exhibits neuroprotective properties against MPTP-induced neurodegeneration.
  • Findings suggest baicalin as a potential therapeutic agent for Parkinson's disease.
  • Further research is warranted to explore long-term effects and therapeutic potential.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...